Cefotaxime

Restricted
C. diff Risk

High

Oral Bioavailability

NA

Approximate Cost

$$

Dosing

Creatinine Clearance >50mL/min/1.73m²Creatinine Clearance <20mL/min/1.73m²Creatinine Clearance <10mL/min/1.73m²Note
Currently on long-term backorder without an estimated release date
50 mg/kg/dose Q6H25 mg/kg/dose Q6HNo change

< 29 weeks postmenstrual age AND ≤28 days old< 29weeks postmenstrual age AND > 28 days old30-36 weeks postmenstrual age AND ≤14 days old30-36 weeks postmenstrual age AND >14 days old37-44 weeks postmenstrual age AND ≤7 days old37-44 weeks postmenstrual age AND >7 days old ≥45 weeks postmenstrual age50 mg/kg/dose IV Q12H50 mg/kg/dose IV Q8H50 mg/kg/dose IV Q12H 50 mg/kg/dose IV Q8H50 mg/kg/dose IV Q12H 50 mg/kg/dose IV Q8H50 mg/kg/dose IV Q6H

2g Q4H

For neonatal use only.

General Information

Adverse Effects

  • GI effects

  • Hypersensitivity reactions

  • C. difficile

Drug Monitoring

Laboratory

  • For IV cephalosporins, Cr weekly

Clinical

  • Hypersensitivity

  • Diarrhea

  • Other GI effects